{"title":"阿那曲唑致不可逆肝毒性:虚弱和药物不良反应","authors":"R. Khuwaileh, T. Green, Subramaniam Nagasayi","doi":"10.15761/ccrr.1000471","DOIUrl":null,"url":null,"abstract":"Laboratory tests showed severe cholestasis: alanine transaminase 33 U/l, alkaline Phosphatase 614 U/l, bilirubin 317 μmol/L, gamma glutamyl transferase 468 U/l, ammonia 90 μmol/L (normal value: <50). CT scan of abdomen confirmed no evidence of hepatic metastases or extra and intrahepatic biliary ductal dilatation. Anastrozole was then discontinued. During the admission, serum alkaline phosphatase and bilirubin continued to worsen despite normal transaminases.","PeriodicalId":72607,"journal":{"name":"Clinical case reports and reviews","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anastrozole induced irreversible hepatotoxicity: Frailty and adverse drug reactions\",\"authors\":\"R. Khuwaileh, T. Green, Subramaniam Nagasayi\",\"doi\":\"10.15761/ccrr.1000471\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Laboratory tests showed severe cholestasis: alanine transaminase 33 U/l, alkaline Phosphatase 614 U/l, bilirubin 317 μmol/L, gamma glutamyl transferase 468 U/l, ammonia 90 μmol/L (normal value: <50). CT scan of abdomen confirmed no evidence of hepatic metastases or extra and intrahepatic biliary ductal dilatation. Anastrozole was then discontinued. During the admission, serum alkaline phosphatase and bilirubin continued to worsen despite normal transaminases.\",\"PeriodicalId\":72607,\"journal\":{\"name\":\"Clinical case reports and reviews\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical case reports and reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/ccrr.1000471\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical case reports and reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/ccrr.1000471","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anastrozole induced irreversible hepatotoxicity: Frailty and adverse drug reactions
Laboratory tests showed severe cholestasis: alanine transaminase 33 U/l, alkaline Phosphatase 614 U/l, bilirubin 317 μmol/L, gamma glutamyl transferase 468 U/l, ammonia 90 μmol/L (normal value: <50). CT scan of abdomen confirmed no evidence of hepatic metastases or extra and intrahepatic biliary ductal dilatation. Anastrozole was then discontinued. During the admission, serum alkaline phosphatase and bilirubin continued to worsen despite normal transaminases.